Almirall and Symatese enter into strategic collaboration

Global pharmaceutical company Almirall and medical device manufacturer Symatese have entered into a global collaboration for the development and commercialisation of customised products in the aesthetics field.

Symatese has granted Almirall an exclusive license for the commercialisation of a new range of hyaluronic acid facial fillers worldwide in exchange for an upfront payment of €7.5m (£6.48m).

Activities will first be focused on the development of a new Hyaluronic Acid-based transformation technology. This technology will enable Almirall to provide a new, safe, efficacious and versatile range of dermal facial fillers that will satisfy patient desires to replace lost facial volume with predictable, natural looking and satisfying results.

Eduardo Sanchiz, CEO of Almirall, commented: “Following the acquisition of ThermiGen, a leading player in the radiofrequency energy-device market, with this collaboration Almirall continues to make progress with its strategic direction into Dermatology and medical Aesthetics. This long-term partnership with Symatese, a leading developer of medical devices, ensures that Almirall will have access to future innovations for the dermal filler market covering our customers unmet needs.“